These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 19627734

  • 1. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
    Zafon C, Obiols G.
    Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
    [Abstract] [Full Text] [Related]

  • 2. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK.
    Cancer; 2010 Jun 15; 116(12):2974-83. PubMed ID: 20564403
    [Abstract] [Full Text] [Related]

  • 3. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
    Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M, Imai K, Cologne J, Soda M, Arihiro K, Fujihara M, Abe K, Hayashi T, Nakashima M, Sekine I, Yasui W, Hayashi Y, Nakachi K.
    Cancer Res; 2008 Sep 01; 68(17):7176-82. PubMed ID: 18757433
    [Abstract] [Full Text] [Related]

  • 4. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.
    Pathol Int; 2007 Jan 01; 57(1):12-20. PubMed ID: 17199737
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. BRAF mutation in thyroid cancer.
    Xing M.
    Endocr Relat Cancer; 2005 Jun 01; 12(2):245-62. PubMed ID: 15947100
    [Abstract] [Full Text] [Related]

  • 12. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.
    Cancer Res; 2003 Aug 01; 63(15):4561-7. PubMed ID: 12907632
    [Abstract] [Full Text] [Related]

  • 13. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
    Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A.
    Oncogene; 2004 Sep 23; 23(44):7436-40. PubMed ID: 15273715
    [Abstract] [Full Text] [Related]

  • 14. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 15. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA.
    Endocrinology; 2006 Feb 15; 147(2):1014-9. PubMed ID: 16254036
    [Abstract] [Full Text] [Related]

  • 16. The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.
    Rusciano MR, Salzano M, Monaco S, Sapio MR, Illario M, De Falco V, Santoro M, Campiglia P, Pastore L, Fenzi G, Rossi G, Vitale M.
    Endocr Relat Cancer; 2010 Mar 15; 17(1):113-23. PubMed ID: 19903742
    [Abstract] [Full Text] [Related]

  • 17. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
    Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE.
    Oncogene; 2005 Oct 06; 24(44):6646-56. PubMed ID: 16007166
    [Abstract] [Full Text] [Related]

  • 18. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
    Salvatore G, Chiappetta G, Nikiforov YE, Decaussin-Petrucci M, Fusco A, Carney JA, Santoro M.
    Eur J Cancer; 2005 Mar 06; 41(5):816-21. PubMed ID: 15763659
    [Abstract] [Full Text] [Related]

  • 19. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
    Ciampi R, Nikiforov YE.
    Endocrinology; 2007 Mar 06; 148(3):936-41. PubMed ID: 16946010
    [Abstract] [Full Text] [Related]

  • 20. BRAF mutations in papillary thyroid carcinoma.
    Wojciechowska K, Lewinski A.
    Endocr Regul; 2006 Dec 06; 40(4):129-38. PubMed ID: 17201587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.